Compare TMCI & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMCI | FLYX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 106.4M |
| IPO Year | 2021 | N/A |
| Metric | TMCI | FLYX |
|---|---|---|
| Price | $1.19 | $2.10 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.77 | N/A |
| AVG Volume (30 Days) | ★ 783.3K | 468.5K |
| Earning Date | 05-07-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,690,000.00 | N/A |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | $7.65 | $15.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.19 | $1.90 |
| 52 Week High | $8.56 | $8.88 |
| Indicator | TMCI | FLYX |
|---|---|---|
| Relative Strength Index (RSI) | 30.44 | 41.74 |
| Support Level | N/A | $1.96 |
| Resistance Level | $3.01 | $2.77 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 1.52 | 12.22 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.